Asia
Fabry disease treatment is going to get new updates as Protalix and Chiesi are seeking approval. This can be a game-changer in the market. Here’s more about it.
Two companies in India have halted vaccine manufacturing, which could be a sign that the pandemic may be coming to an end. For that and more COVID-19 news, continue reading.
When ImmunoGen announced top-line results from the Phase III SORAYA trial in November 2021, the primary endpoint - confirmed objective response rate - was met at 32.4%.
AstraZeneca will showcase its early oncology portfolio at the American Association for Cancer Research set to begin on April 8.
The FDA recommends a randomized trial to adequately assess drug efficacy and safety of P13K inhibitor drug candidates.
The FDA delayed Bristol Myers Squibb’s (BMS) target date for Reblozyl, approved the company’s melanoma drug and Japan accepted BMS’ NDA for Breyanzi.
Terms of the deal provide BiondVax with an option for a worldwide license to develop and commercialize the NanoAbs, which are also known as VHH-antibodies or nanobodies.
Shenandoah Biotechnology is a Warminster, Pennsylvania-based firm that manufactures recombinant proteins, including growth factors and cytokines.
Teva Pharmaceuticals and AbbVie will pay the state of Rhode Island a combined $28.5 million to settle opioid-related claims against the companies.
Zai Lab, a China-focused biopharma company that focuses on treatments for cancer and autoimmune diseases, announced positive data for its clinical trial on Zejula (niraparib) for ovarian cancer.
PRESS RELEASES